JPH0226630B2 - - Google Patents

Info

Publication number
JPH0226630B2
JPH0226630B2 JP56059335A JP5933581A JPH0226630B2 JP H0226630 B2 JPH0226630 B2 JP H0226630B2 JP 56059335 A JP56059335 A JP 56059335A JP 5933581 A JP5933581 A JP 5933581A JP H0226630 B2 JPH0226630 B2 JP H0226630B2
Authority
JP
Japan
Prior art keywords
residue
carbon atoms
alkyl
amino acid
image
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56059335A
Other languages
English (en)
Japanese (ja)
Other versions
JPS572252A (en
Inventor
Esu Boodaa Nikorasu
Bii Suroon Kenesu
Ee Hoganii Sutefuano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JPS572252A publication Critical patent/JPS572252A/ja
Publication of JPH0226630B2 publication Critical patent/JPH0226630B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Manufacturing Of Electrical Connectors (AREA)
  • Steroid Compounds (AREA)
JP5933581A 1980-04-21 1981-04-21 Novel precursor drug of biological activator containing mercapto group Granted JPS572252A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14198180A 1980-04-21 1980-04-21

Publications (2)

Publication Number Publication Date
JPS572252A JPS572252A (en) 1982-01-07
JPH0226630B2 true JPH0226630B2 (cg-RX-API-DMAC7.html) 1990-06-12

Family

ID=22498074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5933581A Granted JPS572252A (en) 1980-04-21 1981-04-21 Novel precursor drug of biological activator containing mercapto group

Country Status (10)

Country Link
US (1) US4443435A (cg-RX-API-DMAC7.html)
EP (1) EP0038541B1 (cg-RX-API-DMAC7.html)
JP (1) JPS572252A (cg-RX-API-DMAC7.html)
AT (1) ATE21388T1 (cg-RX-API-DMAC7.html)
DE (1) DE3175100D1 (cg-RX-API-DMAC7.html)
DK (1) DK172081A (cg-RX-API-DMAC7.html)
ES (1) ES8301197A1 (cg-RX-API-DMAC7.html)
GR (1) GR75219B (cg-RX-API-DMAC7.html)
IE (1) IE52017B1 (cg-RX-API-DMAC7.html)
PT (1) PT72877B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK172081A (da) * 1980-04-21 1981-10-22 Merck & Co Inc Mercaptoforbindelse og fremgangsmaade til fremstilling deraf
JPS57183778A (en) * 1981-04-30 1982-11-12 Nippon Synthetic Chem Ind Co Ltd:The S-(3-phthalidyl)-l-cysteine and its preparation
US4454065A (en) * 1982-05-18 1984-06-12 Smithkline Beckman Corporation Oligopeptide prodrugs
DK302883D0 (da) * 1983-06-30 1983-06-30 Hans Bundgaard Allopurinol prodrugs
CS249576B1 (en) * 1984-12-22 1987-04-16 Antonin Cerny 6-purinyl n-(2-chlorethyl)carbamate and thiocarbamate and method of their production
WO1986004929A1 (fr) 1985-02-22 1986-08-28 Kawasaki Steel Corporation Procede de production de plaques d'acier au silicium unidirectionnelles avec une perte de fer extremement faible
US5203928A (en) * 1986-03-25 1993-04-20 Kawasaki Steel Corporation Method of producing low iron loss grain oriented silicon steel thin sheets having excellent surface properties
JPH0615694B2 (ja) * 1987-04-17 1994-03-02 川崎製鉄株式会社 方向性けい素鋼板の鉄損低減方法
DE3889600T2 (de) * 1987-08-01 1994-09-01 Kawasaki Steel Co Kornorientierte Elektrobleche mit sehr geringen Eisenverlusten und Verfahren zum Herstellen dieser Bleche.
US5120740A (en) * 1989-11-03 1992-06-09 Wisconsin Alumni Research Foundation Prodrugs of 6-mercaptopurine and 6-thioguanine
JPH0723511B2 (ja) * 1989-12-07 1995-03-15 新日本製鐵株式会社 一方向性電磁鋼帯の処理装置
DE69420058T2 (de) * 1993-01-12 2000-04-27 Nippon Steel Corp., Tokio/Tokyo Kornorientiertes Elektroblech mit sehr geringen Eisenverlusten und Herstellungsverfahren
US5823679A (en) * 1993-09-17 1998-10-20 Omega Engineering, Inc. Method and apparatus for measuring temperature including aiming light
FR2773214B1 (fr) 1996-12-11 2002-05-31 Omega Engineering Procede et dispositif pour la mesure par infrarouge de la temperature d'une surface
DE69810852T2 (de) * 1997-07-17 2003-06-05 Kawasaki Steel Corp., Kobe Kornorientiertes Elektrostahlblech mit ausgezeichneten magnetischen Eigenschaften und dessen Herstellungsverfahren
KR100586440B1 (ko) 2001-07-16 2006-06-08 신닛뽄세이테쯔 카부시키카이샤 고자장 철손과 피막 특성이 우수한 초고자속밀도 일방향성전자강판과 그 제조 방법
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
CA2560997A1 (en) * 2004-04-01 2005-10-27 Teva Pharmaceutical Industries Ltd. Delayed release formulations of 6-mercaptopurine
EP2096185B1 (en) 2006-11-22 2014-08-13 Nippon Steel & Sumitomo Metal Corporation Unidirectionally grain oriented electromagnetic steel sheet having excellent film adhesion, and method for manufacturing the same
WO2008074132A1 (en) 2006-12-19 2008-06-26 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
CA2721728A1 (en) * 2008-04-18 2009-10-22 Teva Pharmaceutical Industries Ltd. Treatment of inflammatory bowel disease with 6-mercaptopurine
JP5923879B2 (ja) 2010-06-29 2016-05-25 Ｊｆｅスチール株式会社 方向性電磁鋼板およびその製造方法
JP5927754B2 (ja) 2010-06-29 2016-06-01 Ｊｆｅスチール株式会社 方向性電磁鋼板およびその製造方法
US9330839B2 (en) 2010-08-06 2016-05-03 Jfe Steel Corporation Grain oriented electrical steel sheet and method for manufacturing the same
JP5998424B2 (ja) 2010-08-06 2016-09-28 Ｊｆｅスチール株式会社 方向性電磁鋼板
JP5853352B2 (ja) 2010-08-06 2016-02-09 Ｊｆｅスチール株式会社 方向性電磁鋼板およびその製造方法
JP5593942B2 (ja) 2010-08-06 2014-09-24 Ｊｆｅスチール株式会社 方向性電磁鋼板およびその製造方法
RU2576355C1 (ru) 2011-12-26 2016-02-27 ДжФЕ СТИЛ КОРПОРЕЙШН Текстурированный лист электротехнической стали
KR101638890B1 (ko) 2011-12-27 2016-07-12 제이에프이 스틸 가부시키가이샤 방향성 전자 강판의 철손 개선 장치
JP5761377B2 (ja) 2011-12-27 2015-08-12 Ｊｆｅスチール株式会社 方向性電磁鋼板
CN104024455B (zh) 2011-12-28 2016-05-25 杰富意钢铁株式会社 方向性电磁钢板及其铁损改善方法
US10804015B2 (en) 2011-12-29 2020-10-13 Posco Electrical steel sheet and method for manufacturing the same
WO2013160955A1 (ja) 2012-04-26 2013-10-31 Ｊｆｅスチール株式会社 方向性電磁鋼板およびその製造方法
JP5971157B2 (ja) 2013-03-11 2016-08-17 Ｊｆｅスチール株式会社 塗布装置および塗布方法
JP5668795B2 (ja) 2013-06-19 2015-02-12 Ｊｆｅスチール株式会社 方向性電磁鋼板およびそれを用いた変圧器鉄心
CN105555984B (zh) 2013-09-19 2017-07-07 杰富意钢铁株式会社 方向性电磁钢板及其制造方法
JP6215673B2 (ja) 2013-11-29 2017-10-18 東芝産業機器システム株式会社 ベクトル磁気特性制御材、および、鉄心
KR101639920B1 (ko) 2014-12-26 2016-07-15 주식회사 포스코 방향성 전기강판의 자구미세화 장치 및 그 방법
WO2017066619A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
CA3054528C (en) 2017-02-28 2021-09-07 Jfe Steel Corporation Grain-oriented electrical steel sheet and production method therefor
KR102880080B1 (ko) 2020-11-27 2025-10-31 제이에프이 스틸 가부시키가이샤 방향성 전자 강판 및 그의 제조 방법
CN115724824B (zh) * 2021-09-01 2024-03-15 四川大学 3-(酰胺烷硫基)苯酞类化合物、其制备方法和用途
KR20240113807A (ko) 2022-01-06 2024-07-23 제이에프이 스틸 가부시키가이샤 방향성 전자 강판
EP4582567A4 (en) 2022-09-09 2025-12-24 Jfe Steel Corp GRAIN-ORIENTED ELECTROMAGNETIC STEEL SHEET
KR20240098941A (ko) 2022-12-21 2024-06-28 주식회사 포스코 방향성 전기강판 및 그 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852506A (en) * 1955-10-31 1958-09-16 American Cyanamid Co Method of preparing aminodeoxyglycosidopurines
US2844576A (en) * 1955-11-22 1958-07-22 American Cyanamid Co Preparation of purines
BE733669A (cg-RX-API-DMAC7.html) * 1968-06-04 1969-11-27
US3915958A (en) * 1972-05-22 1975-10-28 Icn Pharmaceuticals 6-Substituted purine nucleotides
JPS49117479A (cg-RX-API-DMAC7.html) * 1973-05-30 1974-11-09
US3957803A (en) * 1975-01-06 1976-05-18 Interx Research Corporation Certain transient pro-drug forms of phenylbutazone
US4275064A (en) * 1976-02-06 1981-06-23 Interx Research Corporation Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents
US4061753A (en) * 1976-02-06 1977-12-06 Interx Research Corporation Treating psoriasis with transient pro-drug forms of xanthine derivatives
US4235887A (en) * 1977-04-13 1980-11-25 The Upjohn Company Process for therapeutic treatment
JPS5589257A (en) * 1978-12-22 1980-07-05 Kanebo Ltd New easily-absorbable sulfur-containing prodrug of non- steroidal antiphlogistic, and their drug compositions
NZ196349A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
DK172081A (da) * 1980-04-21 1981-10-22 Merck & Co Inc Mercaptoforbindelse og fremgangsmaade til fremstilling deraf

Also Published As

Publication number Publication date
JPS572252A (en) 1982-01-07
GR75219B (cg-RX-API-DMAC7.html) 1984-07-13
ES501496A0 (es) 1982-12-01
PT72877A (en) 1981-05-01
US4443435A (en) 1984-04-17
EP0038541B1 (en) 1986-08-13
IE52017B1 (en) 1987-05-27
ATE21388T1 (de) 1986-08-15
ES8301197A1 (es) 1982-12-01
EP0038541A1 (en) 1981-10-28
DK172081A (da) 1981-10-22
PT72877B (en) 1983-03-29
DE3175100D1 (en) 1986-09-18
IE810869L (en) 1982-10-21

Similar Documents

Publication Publication Date Title
JPH0226630B2 (cg-RX-API-DMAC7.html)
MC1068A1 (fr) Derives de la purine et medicaments qui en contienprocede de preparation de derives de la purine nent
BR122013033343B1 (pt) Dimaleato de 4-[(3-cloro-4-fluorfenil)amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il]amino} -7-((s)-tetraidrofuran-3-ilóxi)-quinazolina, seu uso e seu processo de preparação, e composições farmacêuticas
EP0915842A1 (en) Nitrate esters and their use for neurological conditions
JP2001504457A (ja) ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法
JPH0899882A (ja) 気管支拡張組成物
JPH0226629B2 (cg-RX-API-DMAC7.html)
Natelson et al. Preparation of D-, DL-, and L-homoserine lactone from methionine
EP0038161A1 (en) 2,6-Diaminonebularines, their production and use
CA2127066A1 (fr) Derives d'.alpha. amino acides leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPH0556352B2 (cg-RX-API-DMAC7.html)
JPH02503670A (ja) １，２，３，４，１０，１４ｂ‐ヘキサヒドロジベンゾ〔ｃ，ｆ〕ピラジノ〔１，２‐ａ〕アゼピノ誘導体及び１０‐アザ，１０‐オキサ及び１０‐チア類似体
WO2001000621A1 (fr) Derives d'ammonium quaternaire, leur procede de preparation et leur usage en pharmacie
RU2036909C1 (ru) Ацилпроизводные гидроксипиримидинов
EP0143016B1 (fr) Dérivés de 4-(3-alkynyloxy-2-hydroxy-propyl)-piperazin-1-yl-N-phényl acétamide, leur préparation et leur application en thérapeutique
FR2460934A1 (fr) Derives d'isoquinoleine contenant du soufre, procedes pour leur preparation et compositions pharmaceutiques les contenant
JPS60184077A (ja) 抗炎症性オキシム前駆薬
US4228177A (en) 2,3-Dihydro-3-(1H-imidazol-1-ylmethylene)-4H-1-benzothiopyran-4-ones
EP1435964B1 (en) Novel prodrugs of n-h bond-containing compounds and methods of making thereof
JP2019199446A (ja) Ｓ−ｉｃａリボシルホモシステインの製造方法
JP4667042B2 (ja) 新規医薬化合物
WO1992018497A1 (fr) Nouvelles quinolones difluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant
EP0052564B1 (fr) Dérivés de l'acide thiazolyl-2 oxamique substitués en position -4 par un radical thiényle ou furyle, leur préparation et leur utilisation comme médicaments
PT869952E (pt) Derivados de 5-naftalen-1-il-1,3-dioxanos processo para a sua preparacao e sua aplicacao em terapeutica
AU2006212209B2 (en) [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-S-transferase and NADPH quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular